Title
Category
Credits
Event date
Cost
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
$0.00
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.Case #1: A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal UltrasoundDuring this Ace the Case activity, you will learn about risk factors for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis, as well as the current and emerging noninvasive liver assessment tests.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
$0.00
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA. The session, "The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes" was presented by Debbie Cohen, MDDr. Cohen discussed:
- LivDerm
- TME
- 1.00 AANP
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns. In addition, treatment guidelines for AD provide few to no recommendations for selecting therapies and, as a result, treatment selection for each patient can be complex and subjective. New targeted topical therapies are becoming increasingly available, and clinicians must be familiar with the latest clinical data and how to utilize them in clinical practice.
- CMHC
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA. The symposium, "The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes" was presented by Pam R. Taub, MD, Erin D. Michos, MD, and Jennifer Green, MD.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
$0.00
CardioNerds Cofounder Dr. Amit Goyal, Chair of the CardioNerds Heart Failure Committee Dr. Jenna Skowronski, and Episode FIT Lead Dr. Shazli Khan discuss iron deficiency and its impact on heart failure with Dr. Robert Mentz, Chief of Heart Failure at Duke University and principal investigator of the HEART-FID trial. In this case-based discussion, they cover the diagnostic criteria of iron deficiency in heart failure, epidemiology, and strengths and limitations of different iron formulations.
- CMHC
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
$0.00
Welcome to our micro-module webcast on the challenges of managing chronic kidney disease (CKD) and diabetes. After diagnosis, slowing CKD progression in type 2 diabetes (T2D) continues to pose a major challenge. Although new therapies, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have emerged, residual morbidity and mortality persist. Additional strategies are required to slow kidney disease progression, especially targeting inflammation and fibrosis.
- PAINWeek
- 80.00 AANP
- 80.00 ACCME (All Other)
- 80.00 ACCME (MD/DO Only)
- 80.00 ACPE Pharmacy
- 80.00 ANCC
- 80.00 APA
$899.00
PAINWeek remains the US pain conference with the most expansive curriculum providing practical knowledge and tools for healthcare professionals managing acute and chronic pain. Attendees will be able to engage in education that fosters safe, effective, and equitable pain management and treatment practices in clinical practice by providing evidence-based and rigorously tested clinical medical education from expert, experienced, and adequately credentialed medical professionals.
- CMHC
- 4.00 Participation
$0.00
Dr. Ronald M. Krauss, MD, Professor of Medicine at UCSF and Adjunct Professor of Nutritional Sciences at UC Berkeley, and Nina Teicholz, PhD, author and science journalist, co-organized this course on Dietary Approaches to Reversing Type 2 Diabetes. The course is offered as a legacy to the late Dr. Sarah Hallberg, a pioneer in the research and promotion of putting type 2 (T2) diabetes into remission—or “reversal” of the disease, as she preferred to describe the process of restoring average blood sugar (A1c) to normal levels while eliminating the need for all or most medications.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
BTK inhibitors have demonstrated great promise for addressing various treatment challenges for chronic urticaria patients by improving symptom control and more effective targeting of disease pathways.
- CMHC
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
$0.00
Welcome to our webcast on worsening heart failure. Heart failure remains one of the most challenging conditions to manage, with worsening heart failure being a critical area where suboptimal outcomes persist. While foundational therapies such as beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and ARNIs remain integral to heart failure management, advances in our understanding of heart failure pathophysiology have opened the door to newer, innovative therapeutic options, such as SGLT-2i, sCG stimulators and SGLT1/2 inhibitors.